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Abstract
Background: The Venezuelan equine encephalitis (VEE) virus replicon system was used to produce virus-like replicon
particles (VRP) packaged with a number of different VEE-derived glycoprotein (GP) coats. The GP coat is believed to be
responsible for the cellular tropism noted for VRP and it is possible that different VEE GP coats may have different affinities
for cells. We examined VRP packaged in four different VEE GP coats for their ability to infect cells in vitro and to induce both
humoral and cellular immune responses in vivo.
Methodology/Principal Findings: The VRP preparations were characterized to determine both infectious units (IU) and
genome equivalents (GE) prior to in vivo analysis. VRP packaged with different VEE GP coats demonstrated widely varying
GE/IU ratios based on Vero cell infectivity. BALB/c mice were immunized with the different VRP based on equal GE titers and
the humoral and cellular responses to the expressed HIV gag gene measured. The magnitude of the immune responses
measured in mice revealed small but significant differences between different GP coats when immunization was based on
GE titers.
Conclusions/Significance: We suggest that care should be taken when alternative coat proteins are used to package
vector-based systems as the titers determined by cell culture infection may not represent accurate particle numbers and in
turn may not accurately represent actual in vivo dose.
Citation: Kamrud KI, Alterson KD, Andrews C, Copp LO, Lewis WC, et al. (2008) Analysis of Venezuelan Equine Encephalitis Replicon Particles Packaged in
Different Coats. PLoS ONE 3(7): e2709. doi:10.1371/journal.pone.0002709
Editor: Brett Lindenbach, Yale University, United States of America
Received April 7, 2008; Accepted June 19, 2008; Published July 16, 2008
Copyright:  2008 Kamrud et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: NIH grant 5U01AI53876-02
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: kamrud@alphavax.com
Introduction
Venezuelan equine encephalitis (VEE) virus is a member of the
Togaviridae family within the Alphavirus genus. Alphaviruses have
single-stranded, positive-sense, RNA genomes that are capped at
the 59 end and polyadenylated at the 39 end. The viral
nonstructural proteins are encoded for in the 59 two-thirds of
the genome and the structural proteins are encoded in the 39 one-
third of the genome. The nonstructural proteins are translated in
cells directly from the capped input RNA, whereas the structural
proteins are translated from a subgenomic RNA transcribed from
a 26S promoter present on the full-length, negative-stranded,
RNA replication intermediate (reviewed in [1]). A number of live
attenuated VEE virus variants have been described [2–7]. One of
these attenuated VEE viruses (V3014) was used to generate a
replicon system that has been used as a vaccine vector to express a
wide array of genes [8,9]. Such recombinant replicons are
generated by replacing the structural protein coding region with
genes of interest (GOI) generating what is essentially a self-
replicating mRNA. Because the replicon RNA does not contain
the structural genes for VEE, it is a single-cycle, propagation-
defective RNA and replicates only within the cell into which it is
introduced. The replicon RNA can be packaged into virus-like
replicon particles (VRP) by supplying the structural protein genes
of VEE in trans [8].
VEE virus and VRP derived from the VEE replicon system
have a demonstrated lymphotropism [1,10–12]. This character-
istic may, in part, explain the robust antigen-specific immune
responses, both humoral and cellular, detected in animals
immunized with VRP vaccines [8,13–26]. The cell tropism of
VEE virus (or VRP) is believed to be defined by the envelope
proteins that are embedded in the membrane that forms the outer
surface of the particles. Amino acid changes in the envelope
glycoproteins (GP) of VEE viruses have been shown to affect the
relative rate of virus penetration of cells in culture [2], relative
heparan sulfate or hydroxylapatite column binding [7,27], in-vivo
serum virus clearance rates and overall virus attenuation in animal
models [5,7,27–29]. In addition, single or multiple amino acid
changes in the GP coat have been shown to delay VEE virus
progression to, or spread beyond, the draining lymph node of
footpad-inoculated mice, while wild type VEE virus progresses on
into the serum and seeds multiple other organs [5,30]. It is
assumed that VRP packaged with mutant GP coats would
maintain the same surface properties and cell tropisms of the
parent VEE virus harboring the same GP mutation(s) [10].
Considering this, VRP packaged with mutant GP coats, which in
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tropisms and different trafficking to and from draining lymph
nodes, may be less immunogenic than VRP packaged with the
wild type (V3000) VEE GP coat.
Previous experience using VRP packaged with two different
VEE GP coats, V3000 (the wild type Trinidad donkey GP coat)
and V3014, has suggested that different GP coats can induce
different levels of immunogenicity in mice (Kamrud and Smith,
unpublished data) possibly due to lower dendritic cell tropism of
the V3014 GP coat [10]. We were interested in determining the
effects of different GP coats, derived from several live VEE viruses,
on the immunogenicity of single-cycle VRP in BALB/c mice.
Here we report the relative immunogenicity (both cellular and
humoral) in vivo of VRP packaged with GP coats from wild-type
and three attenuated variants of VEE virus in BALB/c mice and
additionally demonstrate that the GP coats impart variable in vitro
Vero cell infectivity relative to one another.
Results
Quantitative reverse transcription PCR (RTqPCR) analysis
of VRP genome copies
A replicon expressing the HIV gag gene was packaged with each
the following VEE GP coats: V3014 GP, V3000 GP, V3042 GP
and TC-83 GP. The GP genes were identified by the name of the
VEE infectious clones from which they were derived; V3000,
V3014, V3042 and TC-83. A list of the specific mutations found in
each of the glycoprotein coats is shown in Table 1. Infectious titers
were determined for each preparation of VRP on Vero cells and
are referred to as infectious units (IU). The number of replicon
genome equivalents (GE) was also determined for each VRP
preparation by quantitative reverse transcription PCR (RTqPCR )
using primers specific for the nsP2 gene region. Determination of
the number of GE in a VRP preparation is an estimate of the total
number of physical particles. A summary of the IU and GE titers is
shown in Table 2. VRP packaged with the V3000 and V3042 GP
coats demonstrated much higher GE/IU ratios than VRP
packaged with V3014 or TC-83 GP coats (Table 2). These data
suggest that a large number of particles packaged with the V3000
and V3042 GP coats are not detected in a normal infectivity assay
carried out in Vero cells.
Effect of NaCl concentration on Vero cell VRP infectivity
The V3014 and TC-83 GP coats contain heparan binding
mutations at E2-209 and E2-120, respectively [8,31]. To
determine whether the high GE/IU ratios for V3000 and
V3042 GP packaged VRP were due to different Vero cell binding
affinities, alternative buffers were used during the cell adsorption
step of the titration assay. Both the pH and NaCl concentration of
the titration buffers were altered from what is normally found in
the MEM medium (pH 7.4, 150 mM NaCl) used for sample
dilution. Reducing the concentration of NaCl also changed the
osmolality of the titration buffers so sucrose was added in place of
NaCl to maintain the osmolality normally found in growth
medium (,270 mOsm). Results of the titration assays are
summarized in Table 3. Reducing the NaCl concentration (from
150 mM to #3.25 mM) in the titration buffer resulted in a
dramatic increase in IU titer for both the V3000 and V3042 GP
packaged VRP. The majority of these particles therefore contain
Table 1. Structural protein coding region and location of glycoprotein mutations in different VEE viruses
VEE virus
infectious clone VEE glycoprotein (amino acid number)
Relative heparan
sulfate binding
E2 (120) E2 (209) E2 (239) E2 (323) E1 (81) E1 (272)
V3000 T E I G F A Weak
V3014 T K N G F T Strong
TC-83 R E N E F A Strong
V3042 T E I G I A Weak
doi:10.1371/journal.pone.0002709.t001
Table 2. Comparison of genome equivalents
VEE GP coat IU Titer
a GE Titer
b GE/IU
V3014 4.90610
9 2.22610
11 45
TC-83 3.00610
10 6.92610
11 23
V3000 3.90610
8 1.40610
12 3590
V3042 5.30610
8 6.60610
11 1245
aInfectious unit (IU) titer determined on Vero cells. IU/ml titer represented.
bGenome equivalent (GE) titer determined by quantitative reverse transcription
PCR. GE/ml titer represented.
doi:10.1371/journal.pone.0002709.t002
Table 3. Effect of pH and NaCl on Vero cell VRP titer
VEE GP coat Titration buffer (pH) IU/ml
c GE
d/IU
V3000 Media (7.4) 1.5610
8 9333
V3000 Phosphate
a (7.0) 6.3610
9 222
Phosphate (7.4) 8.7610
9 160
V3000 Tris
b (7.4) 4.2610
9 333
V3000 Tris (8.0) 4.0610
9 350
V3042 Media (7.4) 5.7610
7 11578
V3042 Phosphate (7.0) 2.1610
9 314
V3042 Phosphate (7.4) 1.8610
9 366
V3042 Tris (7.4) 2.2610
9 300
V3042 Tris (8.0) 1.2610
9 550
aPhosphate: 20 mM sodium phosphate buffer + 5.5% sucrose at designated pH
used to titrate VRP packaged with indicated VEE GP coat.
bTris: 20 mM trishydroxymethylaminomethane + 5.5% sucrose at designated pH
used to titrate VRP packaged with indicated VEE GP coat.
cInfectious unit (IU) titer determined on Vero cells.
dGenome equivalent (GE) titer determined by quantitative reverse transcription
PCR.
doi:10.1371/journal.pone.0002709.t003
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vitro. Little change was noted in apparent VRP titer between the
different pH levels tested, suggesting that the NaCl concentration
of the titration buffer was the most important variable responsible
for this effect. A result of this increase in VRP titers was that the
GE/IU ratios for V3000 and V3042 GP packaged VRP dropped
58 to 38 fold, respectively (Table 3). However, even with the more
sensitive infectivity assay the GE/IU ratios still remained 5 to 10
times higher than the ratios for V3014 and TC-83 GP packaged
VRP. The low NaCl concentration buffers did not increase the IU
titers of V3014 or TC-83 GP packaged VRP (data not shown).
Effect of GP coat on VRP immunogenicity
Because VRP IU titer determined on Vero cells detected only a
minority of the particles packaged with the V3000 or V3042 GP
coats, quantitative RT- PCR was used to determine the relative
GE titer for each preparation. In order to detect possible
differences in immunogenicity imparted to VRP packaged with
different VEE GP coats, a range of GE-based titers were used to
immunize mice (Table 4). All of the VRP used in experiments (in
vitro and in vivo) were purified using the same purification protocol.
Sixteen mice were immunized at three week intervals with each of
three different GE doses. Sera were collected one week after each
immunization. Eight mice per group were sacrificed for T-cell
analysis 7 days after the prime and the remaining animals were
sacrificed 7 days after the boost. The results of GAG-specific
ELISPOT and ELISA analysis are summarized in Figures 1, 2, 3.
There was a dose dependent, antigen-specific, ELISPOT response
detected 7 days after the priming immunization (Figure 1).
Animals immunized with the V3000 GP packaged VRP showed
higher numbers of spot forming cells (SFC) then animals
immunized with VRP packaged with any of the other GP coats
at the 4.5610
7 GE dose tested. A similar result was noted at the
4.5610
5 GE dose, with the exception of the V3042 GP packaged
VRP which were not significantly different from V3000 GP
packaged VRP (Figure 1). Differences were also noted at the
lowest dose tested (4.5610
3 GE), the V3042 GP packaged VRP
demonstrated significantly more SFCs than V3014 or TC-83 GP
packaged VRP (Figure 1). ELISA analysis of serum collected at
this time point revealed that titers above background could not be
detected (data not shown).
ELISPOT analysis of samples collected after the boost revealed
differences between GP coats at each GE dose, with V3042 GP
packaged VRP inducing the highest level of SFCs at each dose
tested (Figure 2). Only the ELISPOT responses detected in
animals immunized with VRP packaged with the V3042 GP coat
remained significant between different GE dosing groups
(Figure 2). ELISA analysis of post-boost samples revealed a dose
response effect between groups receiving different GE doses and
some small but significant differences between GP coats largely in
animals that received the highest VRP dose (Figure 3). The
difference between the V3042 and TC-83 ELISA responses were
mirrored at the 4.5610
7 GE and 4.5610
5 GE doses. The only
other set of responses that remained significantly different between
two different GE doses were V3014 and TC-83 in the 4.5610
7 GE
and 4.5610
3 GE groups.
Discussion
VRP have been shown to induce a broad array of immune
responses to the foreign gene product expressed by the replicon,
including cytotoxic T lymphocytes (CTL), lymphoproliferative
responses and neutralizing antibodies. Moreover, VRP have been
shown to confer protection in animal models against a variety of
diseases that require humoral and/or cellular effector mechanisms
for protection [13–22,32–35].
One of the reasons that VRP vaccines are so potent in their
ability to induce immune responses may relate to their ability to
target dendritic cells (DC), which are the most potent antigen-
presenting cells of the immune system. The lymphotropic nature of
VEE virus has been known for many years, but it has only recently
been appreciated that VEE virus specifically infects DC in the
draining lymph nodes of mice, and VRP target the same cells [10].
VRP also infect human DC in vitro [12]. Recent data have
demonstrated the specific usage of DC SIGN and L-SIGN as
attachment receptors for alphaviruses and may mechanistically
explain their DC-targeting phenotype. In addition to lymphoid
specificity, recent studies suggest that the immunogenicity of
alphavirus replicon vaccines may be also be influenced by the
activation of the innate immune system, via ribonuclease L or a
double-stranded-RNA-dependent proteinkinase (PKR), that occurs
in cells infected with an alphavirus or alphavirus replicon [36–40].
Thus, the DC targeting and high protein expression that stimulate
the adaptive immune responses, along with signaling of the innate
immune system by dsRNA replicative intermediates, combine to
make the VEE replicon system an attractive vaccine vector.
Although VRP have demonstrated ability to induce robust
immune responses only VRP packaged in a few different VEE GP
coats have been tested in animals. VRP packaged with the V3014
GP have been examined the most [13–22,32–35]. Other studies
have included VRP packaged with V3000 GP: [10,41,42], V3010
GP: [10] and V3533 GP: [10]. Because the VRP doses used in
these studies did not take particle to infectious unit ratios into
consideration it is not possible to compare the immune responses
demonstrated between these studies. As such, a direct comparison
of the immunogenicity of VRP packaged with different VEE GP
coats has not been described previously.
Data presented here suggest that large differences in Vero cell
infectivity exist between VRP packaged with the V3000 GP and
V3042 GP coats compared to V3014 GP and TC-83 GP coats.
This is perhaps not unexpected for V3000 GP packaged particles
compared to V3014 GP and TC-83 GP packaged particles
because of the methods used to produce these respective
Table 4. VEE GP coat mouse immunogenicity study design
Group VEE GP coat GE dose
a IU dose
b # animals
1 V3014 4.5610
7 1.00610
6 16
2 V3000 4.5610
7 1.20610
4 16
3 TC-83 4.5610
7 1.90610
6 16
4 V3042 4.5610
7 3.60610
4 16
5 V3014 4.5610
5 1.00610
4 16
6 V3000 4.5610
5 1.20610
2 16
7 TC-83 4.5610
5 1.90610
4 16
8 V3042 4.5610
5 3.60610
2 16
9 V3014 4.5610
3 1.00610
2 16
10 V3000 4.5610
3 1.2 16
11 TC-83 4.5610
3 1.90610
2 16
12 V3042 4.5610
3 3.6 16
aGenome equivalent (GE) titer determined by quantitative reverse transcription
PCR.
bInfectious unit (IU) titer determined on Vero cells.
doi:10.1371/journal.pone.0002709.t004
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attenuated VEE virus with rapid binding and penetration
characteristics on BHK cells [2,43] and the TC-83 GP mutations
were identified in an attenuated VEE virus after multiple cell
culture passages [31,44]. Both GP coats have key attenuating
mutations that map to the E2 coding region and confer a strong
heparan sulfate-binding phenotype [7]. The heparan sulfate-
binding capacity of the V3014 GP and TC-83 GP may explain
why VRP packaged with these coats demonstrate a low GE/IU
ratio based on Vero cell infectivity. It is well accepted that tissue
culture adaptation of VEE virus leads to selection of heparan
sulfate binding mutations in the GP coat [7], but attenuating
mutations in the GP coat of VEE viruses unrelated to heparan
sulfate binding have been identified [5,28]. An example of this is
the V3042 virus. The GP coat of V3042 virus has a PheRIle
amino acid change at position 81 of the E1 protein [6,28] and this
GP coat does not impart a strong heparan sulfate binding
phenotype. The lower heparan sulfate binding capacity of VRP
packaged with the V3042 GP coat (and V3000 GP coat) likely
contributes to a GE/IU ratio, determined on Vero cells, that is 5–
10 times that of V3014 GP and TC-83 GP coat packaged VRP.
The weak heparan sulfate interaction is supported by the apparent
increase in IU titer (and resultant reduction in GE/IU ratio) noted
when VRP titration was carried out in low NaCl concentration
buffers. It is possible that the lower ion concentration in the
titration buffers may have allowed weak heparan sulfate charge
associations with these GP coats that would normally not be strong
enough to facilitate cell binding and VRP entry.
We have previously explored the use of the V3000 GP coat to
package VRP and attempted to determine whether this coat could
impart higher immunogenicity to particles when compared to that
of the V3014 GP coat. Those preliminary results suggested that
V3000 GP packaged VRP induced more robust immune
responses in mice than did V3014 GP packaged VRP, but
differences in the methods used to purify the two VRP made
interpretation of the results difficult (Kamrud and Smith
unpublished results). To eliminate differences in VRP purification,
that may affect immunogenicity, a uniform production process was
used for all VRP used in this study. In addition, particle to
infectious unit ratios, as estimated by measuring GEs, were
measured by RTqPCR to control for differences in particle
number that may not be evident when VRP titer determined on
Vero cells was the sole method used to assess potency.
The greater than 100-fold difference in GE/IU ratios between
V3000 GP and V3014 GP packaged VRP may, in part, explain
the preliminary results alluded to above. To assist in our analysis,
only immune responses shown to be statistically different between
GP coats that occurred in at least two of the tested GE dosing
groups were considered. With this limitation, the majority of
differences that were found between GP coats were seen only at
the T-cell level by cIFN ELISPOT. Interestingly, VRP packaged
with the V3000 GP coat induced the highest ELISPOT results
Figure 1. GAG-specific ELISPOT analysis post prime. Splenocytes were isolated from individual animals and GAG specific gamma interferon
ELISPOT assays were performed to determine the number of antigen-specific cytokine-secreting T cells. Error bars represent 1 standard error.
doi:10.1371/journal.pone.0002709.g001
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induced the highest ELISPOT results after the boost. It is unclear
at this time why this was the case. The ELISPOT data suggest that
induction of T-cell responses may be more sensitive to differences
in VEE GP coat than induction of B-cell responses based on
ELISA. Clearly, VRP induction of T-cell responses occurred
rapidly as GAG-specific cIFN secreting cells could be detected 7
days after the prime while a GAG-specific ELISA response could
not. It is possible that the nature of the GAG antigen is the basis
for the low post prime humoral immune response noted; VRP
packaged with the different GP coats that express an alternative
antigen should be tested in the same manner to explore this
further. Post-boost, the GAG-specific ELISA analysis showed a
dose response effect independent of the GP coat used to package
the VRP. Both the V3014 and V3042 GP VRP demonstrated
significantly higher ELISA responses when compared to TC-83
GP VRP at two different GE dose levels. These data suggest that
VRP packaged with V3014 or V3042 GP coats may be better at
inducing humoral immune responses than TC-83 GP packaged
particles but they are no different than V3000 GP coated particles.
Similar studies have been conducted using either VEE or Sindbis
(SIN) replicon vectors packaged in homologous or heterologous
GP coats, respectively [41]. The results from that study indicated
that the highest humoral and cellular immune responses detected
in immunized animals correlated with the VEE non-structural
genes used in the animals, not with the VEE or SIN GP coats used
to package the VRP [41]. Our data suggest that some of the VEE
GP coats examined here impart large differences in Vero cell
infection capacity which results in a significant under estimation of
the actual particles present in those VRP preparations. When
animals are immunized with VRP packaged with different GP
coats based on genome equivalents rather than Vero cell infectious
units those differences are not mirrored in BALB/c mice based on
the immune responses detected. That is, those particles not
detected by Vero cell-based infection assay (IU) appear to be
functional in vivo in BALB/c mice. Finally, these data suggest that
caution should be taken when examining alternative GP coats
used to package vector-based vaccines (such as adenovirus, adeno-
associated virus, vesicular stomatitis virus and alphavirus-based
vectors) as differences in apparent immunogenicity imparted by
the GP coat may be an artifact of the method/cell type used to
determine IU titer and immunization dose.
Materials and Methods
Cells and media
VRP production and titration were conducted using a certified
Vero cell line derived from a master cell bank prepared from cells
obtained from the World Health Organization. Vero cells were
grown in Minimum Essential Medium (MEM: Invitrogen,
Figure 2. GAG-specific ELISPOT analysis post boost. Splenocytes were isolated from individual animals and GAG specific gamma interferon
ELISPOT assays were performed to determine the number of antigen-specific cytokine-secreting T cells. Error bars represent 1 standard error.
doi:10.1371/journal.pone.0002709.g002
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HyClone, Logan, UT), for expansion before electroporation. After
electroporation Vero cells were seeded into OptiPro (Invitrogen)
serum-free medium with 2 mM glutamine.
Construction of GAG replicon and GP helpers
The Du422 gag gene has been described previously [24]. The gag
gene was cloned into an optimized replicon vector containing an
Encephalomyocarditis virus (EMCV) IRES element and spacer
sequence as described previously [9]. Site directed mutagenesis was
carried out using a QuikChangeH Site-Directed mutagenesis kit
(Stratagene,LaJolla,CA)tointroducea GRA changeat nucleotide
position 3 (nt3A) at the 59 end of the replicon RNA. The nucleotide
3G RA mutation is a known VEE virus attenuating mutation [31]
and was incorporated into the replicon to add an additional
measure of safety to VRP generated with the V3000 GP coat. The
nt3A, IRES-optimized, GAG replicon RNA was packaged with
each of the different VEE GP coats analyzed in this study.
Helpers coding for the GP genes defined by the sequence of the
VEE infectious clones V3000, V3014, V3042 and TC-83 were
constructed. Construction of the V3014 GP helper, pHGP3014,
has been described previously [8]. The V3000 GP gene was
derived from the infectious clone of the wild type virulent Trinidad
donkey strain of VEE [43]. The V3000 GP was cloned as a SpeI
and SphI gene fragment into the V3014 GP helper plasmid
digested with the same enzymes replacing the V3014 GP gene to
generate the V3000 GP helper, pHGP3000. The TC-83 GP gene
was digested from the full length infectious clone of VEE TC-83
virus [31] and cloned into a helper plasmid as described above to
generate the TC-83 GP helper, pHGPTC-83. The V3042 GP
helper was generated by introducing the E1-81 (PheRIle)
mutation [28] into the pHGP3000 GP helper using site directed
mutagenesis (Stratagene) as described above. The V3042 GP
helper, pHGP3042, was sequenced to ensure that no errors were
introduced during the mutagenesis reaction.
RNA transcription, electroporation, VRP production and
VRP titration
VRP were produced by co-electroporating Vero cells with
replicon RNA combined with capsid and GP helper RNAs
(sometimes referred to as the split helper system). The methods
used to in vitro transcribe replicon, capsid and GP RNA and
Figure 3. GAG-specific ELISA analysis post boost. Sera was collected from individual animals 1 week after the booster vaccination and GAG-
specific ELISA analysis was performed. Error bars represent 1 standard error.
doi:10.1371/journal.pone.0002709.g003
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previously [9]. The infectious titer of VRP was determined by
immunofluorescence assay (IFA) using goat anti-VEE nsP2 specific
polyclonal antiserum as the primary antibody and donkey anti-
goat Alexa Fluor 488 (Invitrogen) as the secondary antibody on
methanol fixed Vero cells using a Nikon Eclipse TE300
fluorescence microscope. VRP were serially diluted in MEM
(5% FBS), dilutions were inoculated onto Vero cells and analyzed
18 hr post infection as described above by IFA to determine an
initial IU/ml titer. For VRP titers determined in low NaCl
titration buffers, each VRP preparation was diluted to within two
orders of magnitude of the original IU/ml titer determined in
MEM (5% FBS). The VRP were then diluted 1:10 in one of the
low NaCl titration buffers (20 mM sodium phosphate + 5.5 %
sucrose, pH 7.0 and pH 7.4 or 20 mM Tris + 5.5 % sucrose,
pH 7.4 and pH 8.0) followed by serial 2 fold dilutions in the
respective low NaCl titration buffers. The VRP dilutions were
inoculated onto Vero cells and analyzed as described above by
IFA to determine IU/ml titer. The VRP were tested for the
presence of contaminating replication competent VEE (RCV)
using two blind passages on Vero cells as described previously [9].
VRP purification
VRP were collected 18 hr post-electroporation, by removing the
media and washing the cells with 0.4 M NaCl (salt wash). Some of
the GP coats produced VRP that bound to Vero cells with less
affinity than V3014 GP VRP, thereby resulting in a significant
proportion of VRP in the media. In order to collect all of the VRP
generated with each GP coat and to maintain a uniform
purification method for all VRP the salt wash was combined with
the media from electroporated cells and the pool concentrated 10
fold on a tangential flow filtration (TFF) system with 100,000
molecular weight cutoff Hydrosart membrane (Sartorius, Edge-
wood, NY). A 5 M NaCl /10 mM sodium phosphate pH 7.3
solution was added to the TFF retentate to produce a solution with
a final sodium chloride concentration of 2 M. The solution was
recirculated 5 minutes with the permeate closed and then the
solution was concentrated to one half the original volume. The
solution was diafiltered against 3 volumes of cold phosphate
buffered saline containing 3 mM magnesium chloride. The
permeate of the system was closed, 25,000 U of Benzonase (EM
Science, NJ) was added and the system was allowed to recirculate
for 5 min. The pump was stopped for 60 min and then restarted.
A 5 M sodium chloride /10 mM sodium phosphate pH 7.3
solution was added to the TFF retentate to produce a solution with
a final sodium chloride concentration of 2 M. The solution was
recirculated 5 minutes with the permeate closed and then the
solution was concentrated to one half the original volume. The
solution was diafiltered against 3 volumes of cold 0.5 M sodium
chloride/10 mM sodium phosphate pH 7.3. The TFF retentate
was drained from the system, passed through a 0.2 m filter and
diluted 1:10 into 10 mM Tris buffer, pH 8.0. The diluted solution
was loaded to a 3.5 mL Cellufine sulfate (Chisso, Japan) column at
200 cm/hr. The column was washed with 10 mM Tris, pH 8
followed by 10 mM sodium phosphate, pH 7.3. VRP were eluted
with a step gradient to 1 M sodium chloride/10 mM phosphate,
pH 7.3. Fractions were pooled based upon the A280 absorbance
elution profile and the VRP titer in the pooled fractions was
determined by IFA as described above.
Quantitative reverse transcription PCR (RTqPCR) analysis
of VRP
To determine the number of genome equivalents present in
each different GP coated VRP, a standard one-step RT-qPCR
protocol was performed on an Applied Biosystems 7500 Fast Real
Time PCR System sequence detection system. Amplification was
detected by means of a fluorogenic probe designed to anneal to a
region of the nsP2 gene on the replicon between the two primers.
A5 9 reporter dye (6-FAM) and a 39 quencher dye (BHQ-1) were
attached to the probe. Proximity of the reporter and quencher
dyes resulted in the suppression of reporter fluorescence prior to
amplification. Upon successful amplification of the target region,
the 59 exonuclease activity of DNA polymerase released the
reporter dye from the hybridized probe, resulting in a fluorescent
signal. Purified VEE replicon RNA was used to generate a
standard curve in the assay, and the fluorescent signal of each
VRP sample was measured over forty PCR cycles and compared
to the fluorescent signal of the standards to determine genome
equivalents.
Vaccination of mice and sample collection
Female, 6–8 week old, BALB/c, mice (Charles River Labora-
tory, Kingston, NY) were immunized with VRP produced with the
different GP coats based on genome equivalent (GE) titers. A
summary of the GE titers, the respective Vero cell infectious titer
and the number of animals immunized in each group for each
dose are shown in Table 4. Mice were immunized at 0 and 3
weeks by subcutaneous (SC) injection into the rear footpad. GAG-
specific antibody and T cell responses were monitored 1 week after
each immunization. Blood was collected by retro-orbital bleeds for
all groups. Eight (8) mice from each group were sacrificed 1 week
after each immunization and splenocytes collected from individual
animals for T-cell analysis.
ELISA and ELISPOT analysis
For ELISA analysis, dilutions of sera from GAG-VRP
vaccinated mice were made into PBS containing 1% BSA and
0.05% Tween-20 beginning with 1:40 followed by two fold
dilutions out to 1:2560. Pre-bleed samples were diluted to only
1:40. ELISA plates (Nunc, Rochester, NY), which had been coated
with HIV GAG antigen (0.25 mg/well) in carbonate/bicarbonate
buffer (Sigma-Aldrich, St. Louis, MO) overnight at 4uC, were
incubated with 200 ml/well of blocking buffer (PBS, 3% BSA) at
30uC for 1 hour. Blocked plates were washed three times with 200
ml of PBS. Fifty ml of diluted sera was added to the plates in
duplicate and incubated at 30uC for one hour. Plates were washed
three times with 200 ml PBS. 100 ml of alkaline phosphatase-
conjugated anti-mouse polyvalent immunoglobulin’s (IgG, IgA,
IgM) (Sigma) diluted in blocking buffer (1:500) was added to each
well. Plates with secondary antibody were incubated for 1 hour at
room temperature and then washed three times with 200 ml PBS.
Plates were developed using Fast
TM p-Nitrophenyl phosphate
tablet sets (Sigma) and reading at a wavelength of 405. An OD405
of 0.2 or greater was considered positive.
Splenocytes were isolated from individual animals and GAG
specific gamma interferon ELISPOT assays were performed to
determine the number of antigen-specific cytokine-secreting T
cells. This procedure has been described previously [45].
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